Search Results

Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC

• Authors : Herbst, Roy S.; Giacone, Giuseppe; Marinis, Filippo de

• Source: The New England Journal of Medicine. Oct 1, 2020, Vol. 383 Issue 14, p1328, 12 p.

Record details

C-reactive protein reduction post treatment is associated with improved survival in atezolizumab (anti-PD-L1) treated non-small cell lung cancer patients

• Authors : Patil, Namrata S.; Zou, Wei; Mocci, Simonetta

• Source: PLoS ONE. February 3, 2021, Vol. 16 Issue 2, e0246486

Record details

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.

• Authors : Rittmeyer, Achim; Barlesi, Fabrice; Waterkamp, Daniel

• Source: The Lancet. 2017, Vol. 389, Issue 10066, pages. 255

Record details

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.

• Authors : Fehrenbacher, Louis; Spira, Alexander; Ballinger, Marcus

• Source: The Lancet. 2016, Vol. 387, Issue 10030, pages. 1837

Record details

Built Environment Education in Art Education.

• Authors : Guilfoil, Joanne K.; Sandler, Alan R.; National Art Education Association, Reston, VA.

Subjects: Architecture; Art Education; Built Environment

• Source: 245

Record details

Modeling and simulation of maintenance treatment in first-line non-small cell lung cancer with external validation

• Authors : Han, Kelong; Claret, Laurent; Sandler, Alan

• Source: BMC Cancer. July 13, 2016, Vol. 16 Issue 1

Record details

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

• Authors : Sandler, Alan; Gray, Robert; Perry, Michael C.

• Source: The New England Journal of Medicine. Dec 14, 2006, Vol. 355 Issue 24, p2542, 9 p.

Record details

Education Full Text (H.W. Wilson)

Record details

Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial.

• Authors : Jotte, Robert; Cappuzzo, Federico; Vynnychenko, Ihor

• Source: Journal of Thoracic Oncology; Aug2020, Vol. 15 Issue 8, p1351-1360, 10p

Record details

Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, including patients with EGFR mutations.

• Authors : Reck, Martin; Shankar, Geetha; Lee, Anthony

• Source: Expert Review of Respiratory Medicine; Feb2020, Vol. 14 Issue 2, p125-136, 12p

Record details